New study shows why vaginal gel for AIDS effective on herpes
Summary of story from The New York Times, October 20, 2011
A new study has found the vaginal gel that sharply reduces a woman’s risk of infection with the AIDS virus is even more effective against genital herpes, a much more common risk for young American women.
The study, by researchers from the National Institutes of Health, Gilead Sciences Inc. and universities in Belgium and Italy, suggests that the microbicide gel, which was originally developed to fight AIDS in Africa, could lower the incidence of herpes in many women.
Genital herpes is far more common than AIDS. The World Health Organization estimates that 20 percent of all sexually active adults have it.
In the United States, the Centers for Disease Control and Prevention estimates that 21 percent of sexually active women have it, including 16 percent of all white women and 48 percent of all black women.
While the final gel trial was done in South Africa because AIDS rates there are so high, earlier safety and acceptability tests were done in several countries, including the United States.
The new study, involving lab experiments, was done to explain why the trial worked, said Dr Salim Abdool Karim, a professor of epidemiology at the University of KwaZulu-Natal in South Africa and Columbia University.











